View ValuationNascent Pharma Holdings 将来の成長Future 基準チェック /06現在、 Nascent Pharma Holdingsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jul 17Can B Corp. Files Form 15Can B Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock, no par value under the Securities Exchange Act of 1934, as amended.お知らせ • Mar 29Can B Corp. announced delayed annual 10-K filingOn 03/28/2025, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 14Can B Corp. announced delayed 10-Q filingOn 11/13/2024, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 29Can B Files A Certificate on Form 15 with the U.S. Securities and Exchange CommissionOn October 25, 2024, Can B Corp. (‘Can B’) implemented a holding company reorganization (the ‘Nascent Merger’) pursuant to the Agreement and Plan of Merger (the ‘Merger Agreement’), dated as of October 23, 2024, among Can B, Nascent Pharma Holdings Inc. (‘Nascent’), and Nascent Merger Sub Inc. (‘Merger Sub’), which resulted in Nascent owning all of the outstanding capital stock of Can B. Pursuant to the Nascent Merger, Merger Sub, a direct, wholly owned subsidiary of Nascent and an indirect, wholly owned subsidiary of Can B, merged with and into Can B, with Can B surviving as a direct, wholly owned subsidiary of Nascent. Each share of each class of Can B stock issued and outstanding immediately prior to the Nascent Merger automatically converted into an equivalent corresponding share of Nascent stock, having the same designations, rights, powers and preferences and the qualifications, limitations and restrictions as the corresponding share of Can B stock being converted. Accordingly, upon consummation of the Nascent Merger, Can B’s stockholders immediately prior to the consummation of the Nascent Merger became stockholders of Nascent. The stockholders of Can B will not recognize gain or loss for U.S. federal income tax purposes upon the conversion of their shares in the Nascent Merger. In connection with the Nascent Merger, Can B notified the Financial Industry Regulatory Authority (‘FINRA’) that it planned to complete the Nascent Merger and, in connection therewith, requested that a new trading symbol be assigned to Nascent. FINRA requested that a new notice be submitted to FINRA after the Nascent Merger is complete. As a result, the change in issuer name and trading symbol on the OTCQB Market will not occur until FINRA completes the processing of the name change and assigns Nascent a trading symbol. On October 28, 2024, Can B filed a certificate on Form 15 with the U.S. Securities and Exchange Commission (the ‘Commission’) under the Securities Exchange Act of 1934, as amended (the ‘Exchange Act’) requesting that Can B shares be deregistered under the Exchange Act, and that Can B’s reporting obligations under the Exchange Act be suspended (except to the extent of the succession of Nascent to the Exchange Act Section 12(g) registration and reporting obligations of Can B).お知らせ • Aug 15Can B Corp. announced delayed 10-Q filingOn 08/14/2024, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18Can B Corp. announced delayed 10-Q filingOn 05/16/2024, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Mar 30Can B Corp. announced delayed annual 10-K filingOn 03/29/2024, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 14Can B Corp. announced delayed 10-Q filingOn 11/13/2023, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 12Can B Corp. Announces its Move and Consolidation of its Pure Health Product Operations from Lacey, WA to ColoradoCan B Corp. announced its move and consolidation of its Pure Health Product operations from Lacey, WA to Colorado. This furthers Can B’s corporate consolidations as it previously did with Miami and McMinville operations also relocating to Colorado. The move included relocating all of the Superfood products manufacturing, process, packaging, labeling, and raw materials/ingredients for Integrity Brands by Brooke Burke Body and other brands to the Company’s Fort Morgan facility on County Road 21, known as the “Budweiser Building.” Pure Health Products expects to have the Superfood production in full operation by mid-October 2023. The other production equipment, including bottling lines, capsule machines, tablet presses, coating machines, wet and dry pouch machines, and various packing sealing and coding equipment, was split into two segments between Hakala Research, LLC in Glen Rock, Wyoming, under a use agreement and CO Botanicals building on Energy Road in Fort Morgan, CO known as the “ICS Building.” This equipment will continue production of PHP’s white-label and brand-labeled tinctures, salves, roll-ons, oils, supplements, lotions, and related products, both with and without CBD. This equipment is expected to be operational by the end of October 2023 as the Company also has sufficient products in inventory to meet expected demand for 45-60 days at current usage.お知らせ • May 16Can B Corp. announced delayed 10-Q filingOn 05/15/2023, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 15Can B Corp. announced delayed 10-Q filingOn 11/14/2022, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 16Can B Corp. announced delayed 10-Q filingOn 08/15/2022, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Can B Corp. announced delayed 10-Q filingOn 05/16/2022, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 06Can B Corp. announced delayed annual 10-K filingOn 04/04/2022, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 26Can B Corp. (OTCPK:CANB) acquired 300,000 Square Foot Facility In McMinnville.Can B Corp. (OTCPK:CANB) acquired 300,000 Square Foot Facility In McMinnville on August 25, 2021. Can B Corp. (OTCPK:CANB) completed the acquisition of 300,000 Square Foot Facility In McMinnville on August 25, 2021.お知らせ • May 18Can B Corp. announced delayed 10-Q filingOn 05/17/2021, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 30Can B Corp. (OTCPK:CANB) acquired Pharmacokinetics Tech.Can B Corp. (OTCPK:CANB) acquired Pharmacokinetics Tech on April 29, 2021. Can B Corp. (OTCPK:CANB) completed the acquisition of Pharmacokinetics Tech on April 29, 2021.お知らせ • Apr 02Can B Corp. announced delayed annual 10-K filingOn 03/31/2021, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 19Can B Corp Partners with Signature PR to Launch a New Premier LineCan B Corp. announced its partnership with Signature PR to initiate efforts for the launch of a new premier line. Under the leadership of Annamarie Seabright, Signature PR is developing an expansion plan into spas, salons, high-end retailers, hospitality services and others.お知らせ • Feb 11Can B Corp and Dr. Karl Zarse Launches ImmuneX2Can B Corp. announced that its partnership with Dr. Karl Zarse has launched ImmuneX2, a super immune boosting twice a day AM/PM supplement. The two entities have developed a cooperative medical office affiliate program to share in the revenues of ImmuneX2. According to Dr. Zarse, ImmuneX2 ingredients are correlated with optimizing immune system before need it. The certified organic twice a day AM/PM supplement is developed by a physician and prepackaged for convenient dosing. Consumers have the option for a monthly subscription with auto-renewal for a discount to the suggested retail price via the ImmuneX2 website. Pure Health Products, LLC, a subsidiary of Can B, is manufacturing ImmuneX2 for production under Dr. Zarse’s ImmuneX2 label. Can B will utilize its existing and growing professional medical sales channel that it has built over the past few years with its lineup of other health and wellness branded products, including Duramed and Canbiola to promote ImmuneX2.お知らせ • Sep 24Can B Corp. announced that it has received $0.104 million in funding from EMA Financial LLCCan B Corp. (OTCPK:CANB) announced that it has entered into a securities purchase agreement with EMA Financial LLC to issue a 12% Convertible Promissory Note of the principal amount of $115,000 for gross proceeds of $104,000 on a best efforts basis, on June 15, 2020. The note is issued at an original issuance discount of $11,000 and bear an interest at 12% per year and matures on June 17, 2021. The note is convertible into shares at a price per share equal to 80% of the lowest closing bid price of the company’s common stock during the twenty trading days prior to the date of conversion. The company raised funding through exemption provided under Regulation D.お知らせ • Sep 23Can B Corp. announced that it has received $0.204545 million in funding from The EquiLux Group, LPOn May 12, 2020, Can B Corp. (OTCPK:CANB) closed the transaction. The company issued securities pursuant to exemption provided under Regulation D.お知らせ • Aug 15Can B Corp. announced delayed 10-Q filingOn 08/14/2020, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Nascent Pharma Holdings は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:NASC - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20241-1300N/A6/30/20241-1400N/A3/31/20242-1400N/A12/31/20232-10-1-1N/A9/30/20232-11-2-2N/A6/30/20235-14-3-3N/A3/31/20236-13-3-3N/A12/31/20227-15-4-4N/A9/30/20228-16-5-5N/A6/30/20227-12-7-7N/A3/31/20226-13-9-8N/A12/31/20215-12-8-7N/A9/30/20213-13-8-7N/A6/30/20212-11-5-5N/A3/31/20211-10-4-3N/A12/31/20202-9-2-2N/A9/30/20202-6-1-1N/A6/30/20202-6-2-2N/A3/31/20202-6-3-2N/A12/31/20192-6-4-2N/A9/30/20192-3-4-2N/A6/30/20192-6-3-2N/A3/31/20191-6-2-1N/A12/31/20181-4-1-1N/A9/30/20180-6-1-1N/A6/30/20180-2N/A0N/A3/31/20180-2N/A0N/A12/31/20170-2N/A0N/A9/30/20170-1N/A0N/A6/30/20170-1N/A0N/A3/31/201700N/A0N/A12/31/20160-1N/A0N/A9/30/20160-1N/A0N/A6/30/20160-1N/A0N/A3/31/20160-1N/A0N/A12/31/20150-4N/A0N/A9/30/20150-3N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NASCの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: NASCの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: NASCの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: NASCの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: NASCの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NASCの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 23:34終値2026/05/26 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nascent Pharma Holdings, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関William GregozeskiGreenridge Global LLC
お知らせ • Jul 17Can B Corp. Files Form 15Can B Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock, no par value under the Securities Exchange Act of 1934, as amended.
お知らせ • Mar 29Can B Corp. announced delayed annual 10-K filingOn 03/28/2025, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 14Can B Corp. announced delayed 10-Q filingOn 11/13/2024, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 29Can B Files A Certificate on Form 15 with the U.S. Securities and Exchange CommissionOn October 25, 2024, Can B Corp. (‘Can B’) implemented a holding company reorganization (the ‘Nascent Merger’) pursuant to the Agreement and Plan of Merger (the ‘Merger Agreement’), dated as of October 23, 2024, among Can B, Nascent Pharma Holdings Inc. (‘Nascent’), and Nascent Merger Sub Inc. (‘Merger Sub’), which resulted in Nascent owning all of the outstanding capital stock of Can B. Pursuant to the Nascent Merger, Merger Sub, a direct, wholly owned subsidiary of Nascent and an indirect, wholly owned subsidiary of Can B, merged with and into Can B, with Can B surviving as a direct, wholly owned subsidiary of Nascent. Each share of each class of Can B stock issued and outstanding immediately prior to the Nascent Merger automatically converted into an equivalent corresponding share of Nascent stock, having the same designations, rights, powers and preferences and the qualifications, limitations and restrictions as the corresponding share of Can B stock being converted. Accordingly, upon consummation of the Nascent Merger, Can B’s stockholders immediately prior to the consummation of the Nascent Merger became stockholders of Nascent. The stockholders of Can B will not recognize gain or loss for U.S. federal income tax purposes upon the conversion of their shares in the Nascent Merger. In connection with the Nascent Merger, Can B notified the Financial Industry Regulatory Authority (‘FINRA’) that it planned to complete the Nascent Merger and, in connection therewith, requested that a new trading symbol be assigned to Nascent. FINRA requested that a new notice be submitted to FINRA after the Nascent Merger is complete. As a result, the change in issuer name and trading symbol on the OTCQB Market will not occur until FINRA completes the processing of the name change and assigns Nascent a trading symbol. On October 28, 2024, Can B filed a certificate on Form 15 with the U.S. Securities and Exchange Commission (the ‘Commission’) under the Securities Exchange Act of 1934, as amended (the ‘Exchange Act’) requesting that Can B shares be deregistered under the Exchange Act, and that Can B’s reporting obligations under the Exchange Act be suspended (except to the extent of the succession of Nascent to the Exchange Act Section 12(g) registration and reporting obligations of Can B).
お知らせ • Aug 15Can B Corp. announced delayed 10-Q filingOn 08/14/2024, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18Can B Corp. announced delayed 10-Q filingOn 05/16/2024, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Mar 30Can B Corp. announced delayed annual 10-K filingOn 03/29/2024, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 14Can B Corp. announced delayed 10-Q filingOn 11/13/2023, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 12Can B Corp. Announces its Move and Consolidation of its Pure Health Product Operations from Lacey, WA to ColoradoCan B Corp. announced its move and consolidation of its Pure Health Product operations from Lacey, WA to Colorado. This furthers Can B’s corporate consolidations as it previously did with Miami and McMinville operations also relocating to Colorado. The move included relocating all of the Superfood products manufacturing, process, packaging, labeling, and raw materials/ingredients for Integrity Brands by Brooke Burke Body and other brands to the Company’s Fort Morgan facility on County Road 21, known as the “Budweiser Building.” Pure Health Products expects to have the Superfood production in full operation by mid-October 2023. The other production equipment, including bottling lines, capsule machines, tablet presses, coating machines, wet and dry pouch machines, and various packing sealing and coding equipment, was split into two segments between Hakala Research, LLC in Glen Rock, Wyoming, under a use agreement and CO Botanicals building on Energy Road in Fort Morgan, CO known as the “ICS Building.” This equipment will continue production of PHP’s white-label and brand-labeled tinctures, salves, roll-ons, oils, supplements, lotions, and related products, both with and without CBD. This equipment is expected to be operational by the end of October 2023 as the Company also has sufficient products in inventory to meet expected demand for 45-60 days at current usage.
お知らせ • May 16Can B Corp. announced delayed 10-Q filingOn 05/15/2023, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 15Can B Corp. announced delayed 10-Q filingOn 11/14/2022, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 16Can B Corp. announced delayed 10-Q filingOn 08/15/2022, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Can B Corp. announced delayed 10-Q filingOn 05/16/2022, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 06Can B Corp. announced delayed annual 10-K filingOn 04/04/2022, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 26Can B Corp. (OTCPK:CANB) acquired 300,000 Square Foot Facility In McMinnville.Can B Corp. (OTCPK:CANB) acquired 300,000 Square Foot Facility In McMinnville on August 25, 2021. Can B Corp. (OTCPK:CANB) completed the acquisition of 300,000 Square Foot Facility In McMinnville on August 25, 2021.
お知らせ • May 18Can B Corp. announced delayed 10-Q filingOn 05/17/2021, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 30Can B Corp. (OTCPK:CANB) acquired Pharmacokinetics Tech.Can B Corp. (OTCPK:CANB) acquired Pharmacokinetics Tech on April 29, 2021. Can B Corp. (OTCPK:CANB) completed the acquisition of Pharmacokinetics Tech on April 29, 2021.
お知らせ • Apr 02Can B Corp. announced delayed annual 10-K filingOn 03/31/2021, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 19Can B Corp Partners with Signature PR to Launch a New Premier LineCan B Corp. announced its partnership with Signature PR to initiate efforts for the launch of a new premier line. Under the leadership of Annamarie Seabright, Signature PR is developing an expansion plan into spas, salons, high-end retailers, hospitality services and others.
お知らせ • Feb 11Can B Corp and Dr. Karl Zarse Launches ImmuneX2Can B Corp. announced that its partnership with Dr. Karl Zarse has launched ImmuneX2, a super immune boosting twice a day AM/PM supplement. The two entities have developed a cooperative medical office affiliate program to share in the revenues of ImmuneX2. According to Dr. Zarse, ImmuneX2 ingredients are correlated with optimizing immune system before need it. The certified organic twice a day AM/PM supplement is developed by a physician and prepackaged for convenient dosing. Consumers have the option for a monthly subscription with auto-renewal for a discount to the suggested retail price via the ImmuneX2 website. Pure Health Products, LLC, a subsidiary of Can B, is manufacturing ImmuneX2 for production under Dr. Zarse’s ImmuneX2 label. Can B will utilize its existing and growing professional medical sales channel that it has built over the past few years with its lineup of other health and wellness branded products, including Duramed and Canbiola to promote ImmuneX2.
お知らせ • Sep 24Can B Corp. announced that it has received $0.104 million in funding from EMA Financial LLCCan B Corp. (OTCPK:CANB) announced that it has entered into a securities purchase agreement with EMA Financial LLC to issue a 12% Convertible Promissory Note of the principal amount of $115,000 for gross proceeds of $104,000 on a best efforts basis, on June 15, 2020. The note is issued at an original issuance discount of $11,000 and bear an interest at 12% per year and matures on June 17, 2021. The note is convertible into shares at a price per share equal to 80% of the lowest closing bid price of the company’s common stock during the twenty trading days prior to the date of conversion. The company raised funding through exemption provided under Regulation D.
お知らせ • Sep 23Can B Corp. announced that it has received $0.204545 million in funding from The EquiLux Group, LPOn May 12, 2020, Can B Corp. (OTCPK:CANB) closed the transaction. The company issued securities pursuant to exemption provided under Regulation D.
お知らせ • Aug 15Can B Corp. announced delayed 10-Q filingOn 08/14/2020, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.